Nomogram for predicting disease-free survival among a multicenter cohort of Chinese patients with locally advanced rectal cancer

• Published in: Cancer management and research Vol. 11; pp. 2471 - 2483
• Main Authors: Li, Zhen-Hui, Xie, Pei-Yi, Zhang, Da-Fu, Li, Ya-Jun, Wu, Lin, Dong, Jian, Xiao, Jian, Liu, Zai-Yi
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.03.2019; Dove; Dove Medical Press
• Subjects: Adjuvant chemotherapy; Antigens; Cancer patients; Cancer treatment; Carcinoembryonic antigen; Chemotherapy; Colorectal cancer; disease-free survival; Diseases; Evidence-based medicine; Medical research; nomogram; Original Research; Patient outcomes; Prognosis; rectal cancer; recurrence; Surgery; Tumors; China; recurrence; nomogram; disease-free survival; rectal cancer
• ISSN: 1179-1322; 1179-1322
• DOI: 10.2147/CMAR.S196614

This study aimed to develop and validate a nomogram for predicting 3-year disease-free survival (DFS) among a multicenter cohort of Chinese patients with locally advanced rectal cancer (LARC) who underwent preoperative therapy followed by surgery. This nomogram might help identify patients who would benefit from postoperative adjuvant chemotherapy and close follow-up. All data from 228 patients in two independent Chinese cohorts (118 patients and 110 patients) were pooled and subjected to survival analysis. One cohort's data were used to develop multivariate nomograms based on Cox regression, and the second cohort was used for external validation. The variables were sex, age, clinical tumor stage, tumor location, preoperative therapy protocol, adjuvant chemotherapy, surgical procedure, surgical approach, pTNM stage, tumor deposit, tumor regression grade, lymphovascular invasion, perineural invasion, pretreatment serum carcinoembryonic antigen (CEA) level, preoperative CEA level, and postoperative CEA level. The model's performance was evaluated based on its discrimination, calibration, and clinical usefulness. The nomogram was based on ypT stage and ypN stage, and the C-index values for 3-year DFS were 0.70 in the training cohort (95% confidence interval: 0.62-0.78) and 0.78 in the validation cohort (95% confidence interval: 0.68-0.89). The Hosmer-Lemeshow calibration test revealed good calibration for predicting 3-year DFS in the training and validation cohorts, and decision curve analysis demonstrated that the nomogram was clinically useful. This nomogram including the ypT stage and ypN stage could predict DFS at 3 years after surgery, which may help better identify Chinese patients who would benefit from additional postoperative adjuvant systemic treatment.